Bayan Health sits at No. 204 in our ranking with a Brief Score of 67. Here are the GLP-1 providers we'd weigh against it — ranked on the same six-factor Brief Score, top down.
Prefer a straight head-to-head? CoreAge Rx vs Bayan Health.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
Tyde Wellness is a 50-state compounded-GLP-1 and longevity telehealth platform spanning weight loss, HRT, hair, and peptides.
The widest published catalog in our ranking (telosrx.com): compounded semaglutide and tirzepatide in oral and microdosed forms, plus intranasal NAD+, recovery peptides and bioidentical HRT — all compounded, none FDA-approved, on a LegitScript-certified platform.
Zera Health is a telehealth platform for compounded GLP-1 weight loss — semaglutide from $149/mo, tirzepatide from $199/mo, plus oral and low-dose microdose options.
The cheapest oral semaglutide route in the ranking, priced per route rather than per dose — provided you stay on auto-refill.
FDA warning letter, February 2026 — issued to Strut Health, LLC dba Strut. See the FDA's warning letter database.
ZYP Medical is a men's-health-oriented telehealth practice prescribing compounded GLP-1 medications for weight loss across six states.
Rivo Health is a large nationwide GLP-1 telehealth program (115,000+ members, Trustpilot 4.7) offering compounded semaglutide and tirzepatide as both injections and oral options.
Somi Health is a telehealth weight-loss provider offering compounded GLP-1 medications - compounded semaglutide and tirzepatide injections plus an oral semaglutide tablet.
RENN Health advertises compounded semaglutide as low as $149 a month and tirzepatide at $199, and never publishes what commitment either figure requires.
Rankings reflect the Dose Brief Score — our editorial judgment per the methodology. Pricing and coverage reflect public disclosures at last review and change often — confirm on each provider's site. Not medical advice; see our disclosure.